Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Mar;34(3):515-522.
doi: 10.1038/s41433-019-0539-3. Epub 2019 Jul 29.

An audit of retinal lymphoma treatment at the University of California San Francisco

Bertil Damato  1   2 , Greg J Bever  3 , Dan J Kim  3 , Armin R Afshar  3 , James L Rubenstein  4
Affiliations
Observational Study

An audit of retinal lymphoma treatment at the University of California San Francisco

Bertil Damato et al. Eye (Lond). 2020 Mar.

Abstract

Background/objectives: To evaluate retinal lymphoma treatment at the University of California San Francisco.

Subjects/methods: Prospective observational audit. Patients were treated systemically, usually with: methotrexate, temozolomide, and rituximab induction; etoposide consolidation; and maintenance with lenalidomide or another immunomodulatory agent. Persistent disease was treated initially by ocular radiotherapy or intravitreal melphalan and latterly by vitrectomy.

Results: The cohort comprised eight females and two males. The median age was 58 years (range, 38-73). Ocular manifestations were initially unilateral in four patients. Vitreous and subretinal infiltrates were initially present in 16 and 12 eyes, respectively, with three eyes having vision of 20/200 or worse. Four patients had a history of central nervous system (CNS) lymphoma. The median ophthalmic follow-up was 37 months (range, 8-56). Diagnostic and therapeutic vitrectomy were performed in 10 and 2 eyes, respectively. All patients had systemic chemotherapy and eight received maintenance immunotherapy. Four patients underwent ocular radiotherapy, bilaterally in two. One patient received bilateral intravitreal melphalan injections. Two eyes of four patients developed lymphoma during the study and two patients developed CNS disease. At study close, subretinal deposits were subtle in nine eyes and more prominent in two, whereas vitreous infiltrates were minimal in nine eyes, mild in one and moderate in one. The latest visual acuity was significantly worse than at presentation in two eyes and better in two. All patients were alive with no active CNS disease.

Conclusions: Subretinal lymphomatous infiltrates respond to systemic chemotherapy with immunomodulatory maintenance, but dense vitreous infiltrates require therapeutic vitrectomy.

PubMed Disclaimer

Conflict of interest statement

JLR receives research funding from Genentech and Celgene.

Figures

Fig. 1
Fig. 1
Fundus photographs showing grading of subretinal infiltrates: (1) minimal, subtle flecks; (2) mild, prominent flecks; (3) moderate, confluent flecks/small tumors; and (4) severe, large tumors
Fig. 2
Fig. 2
Initial and final visual acuity (Blue = left eye; Red = right eye)
See this image and copyright information in PMC

References

    1. Araujo I, Coupland SE. Primary vitreoretinal lymphoma–a review. Asia Pac J Ophthalmol (Philos) 2017;6:283–9. - PubMed
    1. Cassoux N, Merle-Beral H, Leblond V, Bodaghi B, Milea D, Gerber S, et al. Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm. 2000;8:243–50. doi: 10.1076/ocii.8.4.243.6463. - DOI - PubMed
    1. Levasseur SD, Wittenberg LA, White VA. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes. JAMA Ophthalmol. 2013;131:50–5. doi: 10.1001/jamaophthalmol.2013.569. - DOI - PubMed
    1. Fend F, Ferreri AJ, Coupland SE. How we diagnose and treat vitreoretinal lymphoma. Br J Haematol. 2016;173:680–92. doi: 10.1111/bjh.14025. - DOI - PubMed
    1. Frenkel S, Hendler K, Siegal T, Shalom E, Pe’er J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92:383–8. doi: 10.1136/bjo.2007.127928. - DOI - PubMed

Publication types